The Biosimilars Council, alongside the Association for Accessible Medicines (AAM), released its 2025 U.S. Generic & Biosimilar Medicines Savings Report—highlighting the promise of these lower cost medicines have in ensuring America’s patients can THRIVE!
In 2024, savings from the use of biosimilars nearly doubled from the previous year, to $20.2 billion. And since their entry to market in 2015, biosimilars have generated $56.2 billion in savings for America’s patients and the U.S. healthcare system. Further, approximately 60 percent of total savings from biosimilar entrants occurred in the past two years.
“In the past year, the biosimilars industry celebrated a decade of pathbreaking progress, including new therapy areas, $56.2 billion in savings for patients and the healthcare system, and 3.3 billion days of patient therapy,” said Giuseppe Randazzo, Interim Executive Director, Biosimilars Council. “However, over the next decade, 118 biologics are expected to lose patent exclusivity, presenting a $234 billion opportunity for biosimilars. But of these 118 biologics, right now only 12 molecules have biosimilars in development. This ‘biosimilar void’ means the sustainability of our industry is not guaranteed – we must double down efforts to ensure America’s patients have access to these lower-cost, effective treatments.”
